Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report

Go Makimoto; Atsushi Shimonishi; Kadoaki Ohashi; Kiichiro Ninomiya; Hisao Higo; Yuka Kato; Masanori Fujii; Toshio Kubo; Eiki Ichihara; Katsuyuki Hotta; Masahiro Tabata; Yoshinobu Maeda; Katsuyuki Kiura

doi:10.1159/000524326

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report

Go Makimoto, Atsushi Shimonishi, Kadoaki Ohashi, Kiichiro Ninomiya, Hisao Higo, Yuka Kato, Masanori Fujii, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx® panel and successfully treated with tepotinib. Although the patient's performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.

Original language	English
Pages (from-to)	494-498
Number of pages	5
Journal	Case Reports in Oncology
Volume	15
Issue number	2
DOIs	https://doi.org/10.1159/000524326
Publication status	Published - May 5 2022

Keywords

MET
Non-small-cell lung cancer
Tepotinib

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000524326

Cite this

Makimoto, G., Shimonishi, A., Ohashi, K., Ninomiya, K., Higo, H., Kato, Y., Fujii, M., Kubo, T., Ichihara, E., Hotta, K., Tabata, M., Maeda, Y., & Kiura, K. (2022). Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report. Case Reports in Oncology, 15(2), 494-498. https://doi.org/10.1159/000524326

Makimoto, G, Shimonishi, A, Ohashi, K , Ninomiya, K , Higo, H, Kato, Y, Fujii, M, Kubo, T, Ichihara, E , Hotta, K , Tabata, M , Maeda, Y & Kiura, K 2022, 'Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report', Case Reports in Oncology, vol. 15, no. 2, pp. 494-498. https://doi.org/10.1159/000524326

@article{1a54b54bb814448db4b5dd3aebefd375,

title = "Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report",

abstract = "Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx{\textregistered} Pan Lung Cancer polymerase chain reaction Panel (AmoyDx{\textregistered} panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx{\textregistered} panel and successfully treated with tepotinib. Although the patient's performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.",

keywords = "MET, Non-small-cell lung cancer, Tepotinib",

author = "Go Makimoto and Atsushi Shimonishi and Kadoaki Ohashi and Kiichiro Ninomiya and Hisao Higo and Yuka Kato and Masanori Fujii and Toshio Kubo and Eiki Ichihara and Katsuyuki Hotta and Masahiro Tabata and Yoshinobu Maeda and Katsuyuki Kiura",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s).",

year = "2022",

month = may,

day = "5",

doi = "10.1159/000524326",

language = "English",

volume = "15",

pages = "494--498",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

number = "2",

}

TY - JOUR

T1 - Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation

T2 - A Case Report

AU - Makimoto, Go

AU - Shimonishi, Atsushi

AU - Ohashi, Kadoaki

AU - Ninomiya, Kiichiro

AU - Higo, Hisao

AU - Kato, Yuka

AU - Fujii, Masanori

AU - Kubo, Toshio

AU - Ichihara, Eiki

AU - Hotta, Katsuyuki

AU - Tabata, Masahiro

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

PY - 2022/5/5

Y1 - 2022/5/5

N2 - Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx® panel and successfully treated with tepotinib. Although the patient's performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.

AB - Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx® panel and successfully treated with tepotinib. Although the patient's performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.

KW - MET

KW - Non-small-cell lung cancer

KW - Tepotinib

UR - http://www.scopus.com/inward/record.url?scp=85130426965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130426965&partnerID=8YFLogxK

U2 - 10.1159/000524326

DO - 10.1159/000524326

M3 - Article

AN - SCOPUS:85130426965

SN - 1662-6575

VL - 15

SP - 494

EP - 498

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 2

ER -

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this